Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

2Q Pharma Results Preview: What Lies Ahead

Executive Summary

The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.

Advertisement

Related Content

Boehringer Cuts 724 US Jobs To 'Reinvent' Pharma Business
Industry Tightens Drug Pricing Message, But Loose Ends Remain
Celltrion/Pfizer Agree To Wait For Mid-Sept US Inflectra Launch
Biogen Anti-LINGO MS Study Failure Removes Upside
AstraZeneca Groomed Paul Hudson For His New Role … At Novartis
Novartis Pulling Out All The Stops To Amp Up Entresto Sales
J&J Not Sweating Remicade Biosimilar Approval
FDA OK's Gilead's 'TAF' Combo HIV Drug Odefsey
Biogen Senses 'Interesting Opportunities' If Financial Markets Remain Challenging
With Parity Pricing, Gilead Relies On Genvoya Safety To Convert From Stribild

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel